The Results of the Use of Autologous Platelet-Rich Plasma as Part of a Comprehensive Treatment Regimen for Uveitis Associated With Systemic Diseases and Accompanied by Macular Edema

• Published in: Oftalʼmokhirurgii͡a︡ = Ophthalmosurgery no. 2; pp. 20 - 25
• Main Authors: Arbenyeva, N.S., Bratko, V.I., Bratko, G.V., Trunov, A.N., Poveshchenko, O.V., Chernykh, V.V.
• Format: Journal Article
• Language: English
• Published: Publishing house "Ophthalmology" 01.08.2020
• Subjects: anti-inflammatory treatment; autologous platelet-rich plasma; macular edema; uveitis
• ISSN: 0235-4160; 2312-4970
• DOI: 10.25276/0235-4160-2020-2-20-25

Purpose. To evaluate the clinical-ophthalmic effectiveness of using of autologous platelet-rich plasma as part of a comprehensive treatment regimen for uveitis associated with systemic diseases and accompanied by macular edema.Material and methods. The study included 120 people (176 eyes) from 18 to 50 years old with uveitis associated with systemic diseases, accompanied by macular edema: 46 men, 74 women. Patients were divided into 2 groups: the main group consisted of patients receiving antiinflammatory treatment and autologous platelet-rich plasma application; control group consisted of patients receiving anti-inflammatory treatment. All patients underwent a comprehensive ophthalmological examination.Results. It was found that autologous platelet-rich plasma application during anti-inflammatory treatment for patients with uveitis associated with systemic diseases and accompanied by macular edema improves best-corrected visual acuity, statistically significant decrease in retinal thickness in fovea and increase in retinal photosensitivity relative to the data obtained in the control group.Conclusion. The use of autologous platelet-rich plasma in combination with anti-inflammatory treatment decreases incidence of relapse of uveitis associated with systemic diseases, contributes to reducing macular edema and improving functional performance.